Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2160)	2/13/2008 12:25:13 PM
From: Jibacoa	Respond to of 3722

GENZ is having problems trying to stay above the $77 level in spite of reporting again double digit improvements on revenues & earnings in the 4thQ. bigcharts.marketwatch.com Its CEO said that they continue to build the company to meet their goal of 20% compound earnings growth through 2011. They expect revenue to reach $4.5-$4.7B in 2008, with the sales of Aldurazyme now reflected in its revenues, under an agreement with BMRN. The earnings are projected to increase to approximately $4.00 in 2008 & to approximately $7.00 by 2011. The stock needs to close above its Jan 17 H of $82.08 before it can make another all time H. The "analysts" have a target of $86.21, but it seems the stock could get to the high nineties.<g> bigcharts.marketwatch.com Bernard